News
-
PSA to develop CPD standards
Wednesday | Jul 2 2025THE Pharmaceutical Society of Australia (PSA) has taken on the role of publishing education standards for CPD, following the retirement of the Australian Pharmacy Council (APC) accreditation standards for CPD activities at the end of this year (PD 01 Jul).
-
Sim “deeply honoured and humbled” as she locks in fourth term
Wednesday | Jul 2 2025THE Pharmaceutical Society of Australia (PSA) has announced the re-election of Associate Professor Fei Sim as National President for a fourth and final term.
-
-
Hartley’s Gripe Water
Wednesday | Jul 2 2025HARTLEY'S Gripe Water is a natural blend of herbal ingredients of dill seed oil, peppermint oil, chamomile and coriander oil.
-
National Pharmacies’ new CEO
Tuesday | Jul 1 2025NATIONAL Pharmacies has appointed business and retail industry leader Mark Smith (pictured) as its new Chief Executive Officer, commencing 28 Jul.
-
TGA strengthens medical device safety
Tuesday | Jul 1 2025NEW measures introduced by the Australian Government will enhance the identification and management of safety concerns related to medical devices, from consumer level devices such as CPAP machines and blood glucose monitors, to hospital equipment and medical implants.
-
Qld pharmacy services permanent
Tuesday | Jul 1 2025QUEENSLANDERS now have permanent access to a broader range of health services for everyday conditions through participating community pharmacies, making it easier for them to receive timely care close to home.
-
APC Dr Erica Sainsbury awards
Tuesday | Jul 1 2025THE Australian Pharmacy Council (APC) has announced that nominations and applications are now open for the APC Dr Erica Sainsbury Awards, 2025.
-
Maximise your day
Tuesday | Jul 1 2025NEW Maxofen from Nova Pharmaceuticals combines paracetamol and ibuprofen for double-action relief from acute pain and fever.
-
Oral CMV Tx PBS listed for transplant patients
Tuesday | Jul 1 2025LIVTENCITY (maribavir) is now listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with post-transplant cytomegalovirus (CMV) infection or disease who are resistant, refractory or intolerant to one or more prior therapies.
